Parametric Portfolio Associates’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Parametric Portfolio Associates’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-51,348	Closed	-$649K	–	4097
2020 Q4	$649K	Buy	51,348 +141	+0.3%	+$1.61K	﹤0.01%	3249
2020 Q3	$503K	Buy	+51,207	New	+$505K	﹤0.01%	3278
2019 Q3	–	Sell	-11,349	Closed	-$136K	–	4022
2019 Q2	$136K	Buy	11,349 +1,089	+11%	+$11.7K	﹤0.01%	3806
2019 Q1	$124K	Sell	10,260 -1,028	-9%	-$15.2K	﹤0.01%	3791
2018 Q4	$142K	Sell	11,288 -30,380	-73%	-$419K	﹤0.01%	3729
2018 Q3	$618K	Sell	41,668 -41,822	-50%	-$658K	﹤0.01%	3329
2018 Q2	$1.41M	Sell	83,490 -3,181	-4%	-$61.8K	﹤0.01%	2875
2018 Q1	$1.99M	Buy	86,671 +58,108	+203%	+$1.29M	﹤0.01%	2632
2017 Q4	$739K	Buy	28,563 +17,947	+169%	+$361K	﹤0.01%	3150
2017 Q3	$157K	Buy	+10,616	New	+$154K	﹤0.01%	3903

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parametric Portfolio Associates's CNCE Position: Q1 2021 in Review

Parametric Portfolio Associates sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 51,348 shares — an estimated $649K sold.

Parametric Portfolio Associates first reported a position in CNCE in Q3 2017 and held it in 10 quarters. The position peaked at $1.99M in Q1 2018. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

Parametric Portfolio Associates reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Parametric Portfolio Associates sold 51,348 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $649K.
Parametric Portfolio Associates first reported a position in Concert Pharmaceuticals, Inc. in Q3 2017 and held it in 10 quarters.
Parametric Portfolio Associates's Concert Pharmaceuticals, Inc. position peaked at $1.99M in Q1 2018.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Parametric Portfolio Associates's 13F filing for Q1 2021, filed 17 May 2021.